Indian pharmaceutical exports are facing significant challenges as supply chain disruptions and doubled freight costs threaten to cost the industry ₹2,500-5,000 crore if conditions persist through March. According to Pharmexcil, these disruptions are squeezing company profits and delaying payments, particularly for firms that already purchased raw materials at higher prices. The crisis comes as Indian pharmaceutical companies continue to find steady growth in the domestic market while navigating challenges in the US market, highlighting the dual nature of the sector's current performance.
West Asia, representing 5.6% of total Indian pharmaceutical exports, is experiencing significant challenges due to geopolitical tensions and shipping disruptions. Countries like the UAE, Saudi Arabia, Oman, Kuwait, and Yemen depend on India for affordable generic drugs, but freight charges have doubled with added surcharges of $4,000-$8,000 per shipment. The region's importance to Indian pharma exports makes these disruptions particularly damaging, as companies face heavy pressure from the logistics cost increases that have made West Asia a key market for Indian pharmaceutical manufacturers.
The export crisis highlights India's heavy reliance on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with nearly 70% of essential drug components coming from outside India, mainly China. This cost-focused model has often depended on China's upstream manufacturing, but past disruptions including the COVID-19 pandemic are pushing for change. Government programs like the Production Linked Incentive (PLI) scheme and plans for Bulk Drug Parks aim to boost domestic API production and lower import dependence, a strategy now seen as even more critical given the current supply chain challenges.
The end of exclusive sales window for a large oncology drug continues to create a slowdown in US sales for finished dosage drug manufacturers, as reported by Moneycontrol. This development highlights the concentration risk that many Indian pharma companies face in their US operations, making the domestic market's steady performance particularly valuable during this transition period. Looking ahead, the US market may see slower growth due to pricing challenges and regulatory reviews, while the recent EU-India trade pact could help Indian exports to Europe by lowering tariffs, though challenges remain including geopolitical risks and the need for continuous innovation into higher-value products.
The current crisis is forcing the pharmaceutical sector to rethink its approach beyond just cost competitiveness to building lasting supply chain strength and more domestic API production. While India is known as the "Pharmacy of the World" for producing 20% of global generics, its market value ranking is lower due to its cost-focused model. ICRA forecasts 7-9% revenue growth in FY2026, driven by strong domestic demand and exports to Europe, though the US market may see slower growth. The focus is shifting from low costs to a broader strategy that includes quality, reliability, and supply chain strength, requiring significant investment and collaboration across the sector.
